Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07414836 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
A Phase 1 study, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT07414836 is a Phase 1 study that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 84 participants.
The verdict
NCT07414836, a Phase 1 study, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).
Interventions
- DRUG Tislelizumab
- DRUG BG-C0979
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07414836
The ClinicalTrials.gov registry entry for NCT07414836 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tislelizumab is the first listed.
NCT07414836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07414836 about?
NCT07414836 is a clinical study titled "A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety...
What is the current status of trial NCT07414836?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-04-13. Estimated completion is 2029-04-30.
What interventions are being tested in trial NCT07414836?
The interventions under investigation include: Tislelizumab (DRUG), BG-C0979 (DRUG).
Who is sponsoring clinical trial NCT07414836?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.